16 rows
25 mg via Oral
Reported in 16 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Psilocybin clinical studies for Anxiety Disorders include 52 structured dose rows across 37 linked trials. Common source-reported dose patterns include 25 mg, 10 mg, 15-25 mg. Interpret these as descriptive trial protocols, not treatment recommendations.
This page summarizes source-structured dosing used in linked human clinical studies. It preserves the source-reported unit, route, frequency, and regimen notes where available.
Patterns group structured dose rows with the same reported dose, route, and regimen type. They preserve source units and do not imply clinical equivalence.
Reported in 16 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 4 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Each row comes from a linked clinical trial intervention. Rows with missing or reviewed-incomplete dosing stay visible instead of being filled by inference.
| Study | Arm | Dose | Route and regimen | Source status |
|---|---|---|---|---|
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence | Psilocybin Psilocybin | 25-40 mg | Oral | flexible two sessions | 2 doses Dose expressed per 70 kg; initial 25 mg/70 kg at session 1, second session may be 25, 30, or 40 mg/70 kg. | Not reviewed existing-data | spiritual-experiences-in-psychedelic-assisted-psychotherapy-case-reports-of-comm |
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | Psilocybin group therapy Psilocybin | Not reported | Oral single dose Optional booster dose on day 0. | Not reviewed a-phase-1-study-of-a-second-experience-with-group-retreat-psilocybin-therapy-for-partial |
A Study of Psilocybin for Major Depressive Disorder (MDD) | Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose Encapsulated synthetic psilocybin; administered with SaS protocol. | Not reviewed existing-data | single-dose-psilocybin-treatment-for-major-depressive-disorder-a-randomized-clin |
Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression: a pilot study (PSILODEP-PILOT) | Psilocybin Psilocybin | 10-25 mg | Oral | multi-dose two sessions | 2 doses Two oral doses: 10 mg and 25 mg, separated by one week. | Not reviewed existing-data | psilocybin-with-psychological-support-for-treatment-resistant-depression-an-open |
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | Psilocybin Psilocybin | 0.3-0.4 mg/kg | Oral | multi-dose two sessions | 2 doses Two doses (0.3 mg/kg and 0.4 mg/kg) given in separate all-day sessions 4 weeks apart; delivered with 12-session MET including preparation and debriefing. | Not reviewed existing-data | psilocybin-assisted-treatment-for-alcohol-dependence-a-proof-of-concept-study |
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | Psilocybin Psilocybin | 0.2 mg/kg | Oral | fixed single dose | 1 dose Capsule; 6-hour monitored session. | Not reviewed existing-data | pilot-study-of-psilocybin-treatment-for-anxiety-in-patients-with-advanced-stage- |
Effects of Psilocybin in Post-Treatment Lyme Disease | Psilocybin Psilocybin | 15-25 mg | Oral two sessions | 2 doses Session 1: 15 mg; Session 2: 15 mg or 25 mg. | Not reviewed existing-data | pilot-study-of-psilocybin-in-patients-with-post-treatment-lyme-disease |
Evaluation of Psilocybin (TRP-8802) to Decrease Hyperphagia | Open Label Oral Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose TRP-8802 (psilocybin) single 25 mg oral dose | Not reviewed existing-data | an-open-label-pilot-study-of-psilocybin-assisted-therapy-for-binge-eating-disorder |
Frontline Clinician Psilocybin Study | Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose Usona Institute psilocybin, single 25 mg session with pre- and post-dose psychotherapy. | Not reviewed existing-data | psilocybin-therapy-for-clinicians-with-symptoms-of-depression-from-frontline-car |
Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018) | TRD patients Psilocybin | 10 mg | Oral | fixed single dose | 1 dose Initial safety dose | Not reviewed existing-data | patients-accounts-of-increased-connectedness-and-acceptance-after-psilocybin-for |
Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018) | TRD patients Psilocybin | 25 mg | Oral | fixed single dose | 1 dose Subsequent treatment dose administered 1 week after the first dose | Not reviewed existing-data | patients-accounts-of-increased-connectedness-and-acceptance-after-psilocybin-for |
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia | Oral Psilocybin + Therapy Psilocybin | 15-25 mg | Oral two doses, 2 weeks apart | 2 doses Capsule formulation; second dose 25 mg at 2 weeks. | Not reviewed existing-data | preliminary-safety-and-effectiveness-of-psilocybin-assisted-therapy-in-adults-wi |
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout (PAPR) | MBSR + Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose Single 25 mg oral psilocybin given in an 8-hour group session (1:1 therapist-to-participant ratio). | Not reviewed existing-data | psilocybin-assisted-group-psychotherapy-mindfulness-based-stress-reduction-mbsr- |
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care | PATH Psilocybin | 25 mg | Oral single dose | 1 dose Single 25 mg oral psilocybin dose. | Not reviewed existing-data | psilocybin-assisted-therapy-for-demoralisation-in-hospice-patients-feasibility-s |
Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder | Standard setting Psilocybin | 25 mg | Oral two sessions | 2 doses Standard set-and-setting; second session at 4 weeks (participant may choose Visual Healing or standard). | Not reviewed existing-data | nature-themed-video-intervention-may-improve-cardiovascular-safety-of-psilocybin |
Pilot Trial of Visual Healing in Psilocybin-assisted Therapy for Alcohol Use Disorder | Visual Healing Psilocybin | 25 mg | Oral two sessions | 2 doses First session with Visual Healing; second session at 4 weeks (participant may choose Visual Healing or standard). | Not reviewed existing-data | nature-themed-video-intervention-may-improve-cardiovascular-safety-of-psilocybin |
Psilocybin – Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Low dose psilocybin Psilocybin | 0.1 mg/kg | Oral single dose | 1 dose 0.1 mg/kg oral capsule | Not reviewed existing-data | psilocybin-assisted-therapy-for-major-depressive-disorder-an-exploratory-placebo |
Psilocybin – Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Medium dose psilocybin Psilocybin | 0.3 mg/kg | Oral single dose | 1 dose 0.3 mg/kg oral capsule | Not reviewed existing-data | psilocybin-assisted-therapy-for-major-depressive-disorder-an-exploratory-placebo |
Psilocybin Cancer Anxiety Study | Psilocybin Psilocybin | 0.3 mg/kg | Oral | fixed single dose | 1 dose Single dose; crossover at 7 weeks; follow-up to 6 months. | Not reviewed existing-data | rapid-and-sustained-symptom-reduction-following-psilocybin-treatment-for-anxiety |
Psilocybin for the Treatment of Cluster Headache | Psilocybin 0.0143 mg/kg Psilocybin | 0.014 mg/kg | Oral | multi-dose three sessions (5 days apart) | 3 doses Weight-based option 0.0143 mg/kg or fixed 1 mg option. | Not reviewed existing-data | psilocybin-pulse-regimen-reduces-cluster-headache-attack-frequency-in-the-blinde |
Psilocybin for the Treatment of Cluster Headache | Psilocybin 0.143 mg/kg Psilocybin | 0.143 mg/kg | Oral | multi-dose three sessions (5 days apart) | 3 doses Weight-based option 0.143 mg/kg or fixed 10 mg option. | Not reviewed existing-data | psilocybin-pulse-regimen-reduces-cluster-headache-attack-frequency-in-the-blinde |
Psilocybin for Treatment of Obsessive Compulsive Disorder | High-dose Psilocybin Psilocybin | 300 mcg/kg | Oral weekly | 8 doses | Not reviewed existing-data | a-randomized-clinical-trial-of-repeated-doses-of-psilocybin-for-the-treatment-of-obsessive |
Psilocybin for Treatment of Obsessive Compulsive Disorder | Low-dose Psilocybin Psilocybin | 100 mcg/kg | Oral weekly | 8 doses | Not reviewed existing-data | a-randomized-clinical-trial-of-repeated-doses-of-psilocybin-for-the-treatment-of-obsessive |
Psilocybin for Treatment-Resistant Depression | Delayed treatment Psilocybin | 25 mg | Oral single dose, repeat dosing if relapse criteria met | 3 doses Fixed 25 mg oral psilocybin. Participants who relapsed could receive up to two repeat doses, for a total of up to three dosing sessions. | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-treatment-resistant-depression-in-bipolar- |
Psilocybin for Treatment-Resistant Depression | Immediate treatment Psilocybin | 25 mg | Oral single dose, repeat dosing if relapse criteria met | 3 doses Fixed 25 mg oral psilocybin. Participants who relapsed could receive up to two repeat doses, for a total of up to three dosing sessions. | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-treatment-resistant-depression-in-bipolar- |
Psilocybin in Alcohol Use Disorder With Comorbid Depression (PAD) | Psilocybin 1 mg (control) Psilocybin | 1 mg | Oral two sessions | 2 doses Inactive psilocybin control (1 mg) administered on same schedule; same accompaniment and assessments. | Not reviewed existing-data | psilocybin-in-alcohol-use-disorder-and-comorbid-depressive-symptoms-results-from |
Psilocybin in Alcohol Use Disorder With Comorbid Depression (PAD) | Psilocybin 25 mg Psilocybin | 25 mg | Oral two sessions | 2 doses Two administrations 3 weeks apart; patient accompanied during session (~6 hours); preparation day before and integration day after. | Not reviewed existing-data | psilocybin-in-alcohol-use-disorder-and-comorbid-depressive-symptoms-results-from |
Psilocybin Therapy for Depression and Anxiety in Parkinson’s Disease (PDP) | Psilocybin therapy Psilocybin | 10 mg | Oral single dose First session: 10 mg oral psilocybin with psychological support and monitoring. | Not reviewed existing-data | psilocybin-therapy-for-mood-dysfunction-in-parkinsons-disease-an-open-label-pilo |
Psilocybin Therapy for Depression and Anxiety in Parkinson’s Disease (PDP) | Psilocybin therapy Psilocybin | 25 mg | Oral single dose Second session (conditional, ~2 weeks later): 25 mg oral psilocybin with psychological support and monitoring. | Not reviewed existing-data | psilocybin-therapy-for-mood-dysfunction-in-parkinsons-disease-an-open-label-pilo |
Psilocybin Therapy for Depression in Bipolar II Disorder (BAP) | Psilocybin therapy Psilocybin | 10-25 mg | Oral one or two sessions | 2 doses 10–25 mg oral; second dose optional ~3 weeks after the first; psychological support and clinician safety monitoring. | Not reviewed existing-data | an-open-label-dose-escalation-trial-of-psilocybin-assisted-therapy-for-bipolar-2 |
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms | Psilocybin + escitalopram Psilocybin | 25 mg | Oral | multi-dose multiple dosing days Psilocybin administered on dosing days. Dose data found during issue #220 source review. | Source Backed paper-text | paper:body-mass-index-bmi-does-not-predict-responses-to-psilocybin tered in a supportive setting. Data were pooled across three trials conducted at the Centre for Psychedelic Research, Imperial College London, totalling 77 individuals receiving a 25 mg dose of psilocybin. When controlling for age, sex, and study, evidence supported the null hypothesis that BMI does not predict overall intensity of the altered state (total ASC), |
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms | Psilocybin + placebo Psilocybin | Not reported | Oral multiple dosing days Psilocybin administered on dosing days; daily placebo for 6 weeks. | Not reviewed trial-of-psilocybin-versus-escitalopram-for-depression |
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | Group therapy + psilocybin Psilocybin | Needs review | Oral single dose One individual oral psilocybin treatment session; dose not stated in registry fragment. Supplement is not parsed as PDF: paper:psilocybin-assisted-group-therapy-for-demoralized-older-long-term-aids-survivor- / Supplement 1 | Supplement is not parsed as PDF: paper:psilocybin-assisted-group-therapy-for-demoralized-older-long-... | Needs Review needs-review | psilocybin-assisted-group-therapy-for-demoralized-older-long-term-aids-survivor- |
Psilocybin-assisted psychotherapy for the treatment of depression and anxiety associated with life-threatening illness | Psilocybin 25 mg Psilocybin | 25 mg | Oral single dose | 1 dose Single supervised oral capsule; drug packaging returned | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-depression-and-anxiety-associated-with-lif |
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | Psilocybin + therapy Psilocybin | 25 mg | Oral single dose 25 mg oral psilocybin capsule administered during the retreat psilocybin session, with group and individual therapy support. | Not reviewed existing-data | group-retreat-psilocybin-therapy-for-people-with-metastatic-cancer-with-symptoms-of-anxiety-and |
Psilocybin-Assisted Treatment Naturalistic Observational Study: Mood and Personality Moderators (Irrmischer / Engelbregt, Netherlands 2025) | Psilocybin-assisted treatment program Psilocybin | 25 mg | Oral | fixed single dose | 1 dose Administered via fresh truffle sclerotia; combined with preparatory therapy (1h online, 2h in-person, 1h practical) and integration therapy (2h in-person day after, 1h online 1 week later). | Not reviewed existing-data | moderating-factors-in-psilocybin-assisted-treatment-affecting-mood-and-personali |
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | Psilocybin-assisted Psilocybin | 30 mg | Oral | fixed single dose | 1 dose 30 mg per 70 kg; single day-long session | Not reviewed existing-data | psilocybin-occasioned-mystical-experiences-in-the-treatment-of-tobacco-addiction |
Psychopharmacology of Psilocybin in Cancer Patients | High then low Psilocybin | Needs review | Oral | multi-dose two sessions | 2 doses Sequence: high-dose then low-dose; exact dose values per protocol. paper:psilocybin-produces-substantial-and-sustained-decreases-in-depression-and-anxiet: Arm "High then low" combines low/high dose periods; manual sequence mapping needed. | supplement:psilocybin-produces-substantial-and-sustained-decrea... | Needs Review needs-review | psilocybin-produces-substantial-and-sustained-decreases-in-depression-and-anxiet |
Psychopharmacology of Psilocybin in Cancer Patients | Low then high Psilocybin | Needs review | Oral | multi-dose two sessions | 2 doses Sequence: low-dose then high-dose; exact dose values per protocol. paper:psilocybin-produces-substantial-and-sustained-decreases-in-depression-and-anxiet: Arm "Low then high" combines low/high dose periods; manual sequence mapping needed. | supplement:psilocybin-produces-substantial-and-sustained-decrea... | Needs Review needs-review | psilocybin-produces-substantial-and-sustained-decreases-in-depression-and-anxiet |
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Psilocybin Psilocybin | 25 mg | Oral | fixed single dose | 1 dose Single oral dose of 25 mg psilocybin administered in the Biological Studies Unit. | Not reviewed existing-data | pilot-study-of-single-dose-psilocybin-for-serotonin-reuptake-inhibitor-resistant |
Safety and efficacy of psilocybin-assisted psychotherapy for Generalised Anxiety Disorder [Psi-GAD-1]: a randomised triple-blind active-placebo-controlled trial | Psilocybin + therapy Psilocybin | 25-30 mg | Oral two sessions | 2 doses Dose 1 = 25 mg; Dose 2 = 25 mg (or increased to 30 mg per predefined response criteria). | Not reviewed existing-data | participant-experiences-of-therapeutic-touch-in-psilocybin-assisted-therapy |
Safety, Tolerability, and Efficacy of Psilocybin in Patients With Obsessive-Compulsive Disorder: A Phase I Modified Dose-Escalation Study | High Dose (HD) Psilocybin | 300 mcg/kg | Oral | titrated single dose | 1 dose Assigned in escalating order | Not reviewed existing-data | safety-tolerability-and-efficacy-of-psilocybin-in-9-patients-with-obsessive-comp |
Safety, Tolerability, and Efficacy of Psilocybin in Patients With Obsessive-Compulsive Disorder: A Phase I Modified Dose-Escalation Study | Low Dose (LD) Psilocybin | 100 mcg/kg | Oral | titrated single dose | 1 dose Assigned in escalating order | Not reviewed existing-data | safety-tolerability-and-efficacy-of-psilocybin-in-9-patients-with-obsessive-comp |
Safety, Tolerability, and Efficacy of Psilocybin in Patients With Obsessive-Compulsive Disorder: A Phase I Modified Dose-Escalation Study | Medium Dose (MD) Psilocybin | 200 mcg/kg | Oral | titrated single dose | 1 dose Assigned in escalating order | Not reviewed existing-data | safety-tolerability-and-efficacy-of-psilocybin-in-9-patients-with-obsessive-comp |
Safety, Tolerability, and Efficacy of Psilocybin in Patients With Obsessive-Compulsive Disorder: A Phase I Modified Dose-Escalation Study | Very Low Dose (VLD) Psilocybin | 25 mcg/kg | Oral | fixed single dose | 1 dose Inserted randomly and in double-blind fashion | Not reviewed existing-data | safety-tolerability-and-efficacy-of-psilocybin-in-9-patients-with-obsessive-comp |
Safety, tolerability, and feasibility of psilocybin-facilitated treatment for methamphetamine use disorder: A pilot study (Psi-MA) | Psilocybin + therapy Psilocybin | 25 mg | Oral single dose | 1 dose 25 mg oral capsule administered 1–2 days after last preparatory session; supervised dosing day (~8 hours). | Not reviewed existing-data | psilocybin-assisted-psychotherapy-for-methamphetamine-use-disorder-a-pilot-open- |
Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer | Group psilocybin Psilocybin | 25 mg | Oral | multi-dose single dose | 1 dose 8-hour group psilocybin session; dose per protocol (not specified in registry fragment). Dose data found during issue #220 source review. | Source Backed paper-text | paper:group-format-psychedelic-assisted-therapy-interventions-observations-and-impress ng screening and consenting, 4-6 participants per cohort (with three total cohorts) were enrolled in a protocol involving 3 120 min group preparatory sessions, a single high-dose (25 mg) group psilocybin session, and 3 subsequent group integration sessions. Primary clinical outcomes are still in process of data collection and analysis. Qualitative data was gather |
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density | Psilocybin Psilocybin | 25 mg | Oral single dose | 1 dose | Not reviewed existing-data | short-term-and-late-term-effects-of-psilocybin-on-symptoms-in-major-depression-a-randomized-clin |
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder | Psilocybin 25mg Psilocybin | 25 mg | Oral single dose | 1 dose 5 × 5 mg capsules (single session) | Not reviewed existing-data | psilocybin-assisted-group-therapy-in-patients-with-cancer-diagnosed-with-a-major |
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | High dose Psilocybin | 25 mg | Oral | fixed single dose | 1 dose Dose-finding, high dose arm per protocol. | Not reviewed existing-data | single-dose-psilocybin-for-a-treatment-resistant-episode-of-major-depression |
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | Low dose Psilocybin | 1 mg | Oral | fixed single dose | 1 dose Dose-finding, low dose arm per protocol. | Not reviewed existing-data | single-dose-psilocybin-for-a-treatment-resistant-episode-of-major-depression |
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | Medium dose Psilocybin | 10 mg | Oral | fixed single dose | 1 dose Dose-finding, medium dose arm per protocol. | Not reviewed existing-data | single-dose-psilocybin-for-a-treatment-resistant-episode-of-major-depression |